JPMorgan raised Regeneron Pharmaceuticals (NASDAQ:REGN) price target from $900 to $950

By / / JPMorgan, Regeneron Pharmaceuticals

JPMorgan analyst Chris Schott maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $900 to $950.

Scroll to Top